Rivaroxaban concentration in patients with deep vein thrombosis who reported thrombus progression or minor hemorrhagic complications: first Polish experience

Zalewski, J; Rychlak, Radosław; Góralczyk, Tadeusz; Undas, Anetta

doi:10.20452/pamw.2470

Cited by 12 publications

(15 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…23 Rivaroxaban concentrations were measured by the anti -Xa chromogenic assay, Biophen DiXaI (Hyphen Biomed, Neuville -sur -Oise, France), according to the manufacturer's instructions. 24 We arbitrarily used the cutoff vaule of 30 µg/l 25 and prespecified the group with low rivaroxaban concentrations (≤30 μg/l) and the group with high rivaroxaban concentrations (>30 μg/l).…”

Section: Discussionmentioning

confidence: 99%

Plasma clot permeability and lysability determined on rivaroxaban and clinical outcomes in patients with venous thromboembolism: a cohort study

Frączek¹,

Krzysztofik²,

Stanisz³

et al. 2019

Polish Archives of Internal Medicine

Self Cite

View full text Add to dashboard Cite

INTRODUCTION Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), afflicts over 1 million people in Europe annually. 1 The 1-year incidence of recurrent VTE is approximately 2% among patients receiving direct oral anticoagulants (DOACs) or vitamin K antagonists (VKAs), 2 and rises to 11% at 1 year and 30% at 5 years among individuals following unprovoked VTE after cessation of anticoagulation. 3 The main established risk factors predisposing to VTE recurrence include older age, male sex, high body mass index (BMI), active cancer, unprovoked VTE, proximal DVT or PE, antiphospholipid antibody syndrome, short duration of anticoagulant

show abstract

Section: Discussionmentioning

confidence: 99%

Plasma clot permeability and lysability determined on rivaroxaban and clinical outcomes in patients with venous thromboembolism: a cohort study

Frączek¹,

Krzysztofik²,

Stanisz³

et al. 2019

Polish Archives of Internal Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…The most common tests used for this purpose are calibrated quantitative anti-factor-Xa assays for factor Xa inhibitors or the Hemoclot assays measuring dilute TT in patients on dabigatran. These tests may not be readily available, but in some labs they are performed 24/7 and their results are available up to 2 h [51, 52, 55]. …”

Section: Bleeding Managementmentioning

confidence: 99%

Antithrombotic management in patients with percutaneous coronary intervention requiring oral anticoagulation

Zalewski¹,

Undas²

2016

pwki

Self Cite

View full text Add to dashboard Cite

The dynamic evolution of therapeutic options including the use of vitamin K antagonists (VKA), non-vitamin K oral anticoagulants (NOAC), more potent antiplatelet drugs as well as new generation drug-eluting stents could lead to the view that the current recommendations on the management of patients with percutaneous coronary intervention (PCI) requiring oral anticoagulation do not keep up with the results of several clinical studies published within the last 5 years. In the present overview, we summarize the recent advances in antithrombotic management used in atrial fibrillation patients undergoing PCI for stable coronary artery disease or acute coronary syndrome (ACS). The safety and efficacy of prasugrel and ticagrelor taken with oral anticoagulants also remain to be established in randomized trials; therefore the P2Y12 inhibitor clopidogrel on top of aspirin or without is now recommended to be used together with a VKA or NOAC. It is still unclear which dose of a NOAC in combination with antiplatelet agents and different stents should be used in this clinical setting and whether indeed NOAC are safer compared with VKA in such cardiovascular patients. Moreover, we discuss the use of anticoagulation in addition to antiplatelet therapy for secondary prevention in patients with ACS. To minimize bleeding risk in anticoagulated patients following PCI or ACS, the right agent should be prescribed to the right patient at the right dose and supported by regular clinical evaluation and laboratory testing, especially assessment of renal function when a NOAC is used.

show abstract

“…The effect of apixaban can be qualitatively evaluated with modified PT, while dabigatran -with dilute thrombin time or anti-factor II assay. When necessary and feasible, concentration of NOACs can be directly measured in plasma [79,80].…”

Section: Oral Anticoagulants In Copdmentioning

confidence: 99%

Arterial and Venous Thromboembolism in Chronic Obstructive Pulmonary Disease: From Pathogenic Mechanisms to Prevention and Treatment

Mejza

Lamprecht

Niżankowska‐Mogilnicka

et al. 2015

Advances in Respiratory Medicine

Self Cite

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) affects approximately 10% of adults older than 40 years and is an important causes of disability and death in elderly subjects. A large proportion of COPD patients suffer from cardiovascular comorbidities. Thromboembolic events contribute considerably to morbidity and mortality in these subjects. This review summarizes the current evidence regarding the association of COPD with increased thromboembolic risk. We discuss multiple mechanisms potentially linking these conditions and available pharmacological interventions reducing the risk of thrombotic arterial and venous events with special attention paid to new oral anticoagulants.

show abstract

Rivaroxaban concentration in patients with deep vein thrombosis who reported thrombus progression or minor hemorrhagic complications: first Polish experience

Cited by 12 publications

References 7 publications

Plasma clot permeability and lysability determined on rivaroxaban and clinical outcomes in patients with venous thromboembolism: a cohort study

Plasma clot permeability and lysability determined on rivaroxaban and clinical outcomes in patients with venous thromboembolism: a cohort study

Antithrombotic management in patients with percutaneous coronary intervention requiring oral anticoagulation

Arterial and Venous Thromboembolism in Chronic Obstructive Pulmonary Disease: From Pathogenic Mechanisms to Prevention and Treatment

Contact Info

Product

Resources

About